Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 30, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
June 22, 2023 03:30 ET
|
Madrigal Pharmaceuticals, Inc.
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data support findings on...
Madrigal Pharmaceuticals Supports International NASH Day on June 8
June 06, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
June 01, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
May 11, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
May 09, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom abstracts accepted for presentation at EASL,...
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
April 18, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
February 23, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in the first half of 2023Madrigal reports year end cash, cash...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
February 08, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
January 06, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of...